Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (864)	2/19/1999 10:07:00 PM
From: software salesperson	Respond to of 3202

rman, how about this,i'll post,you analyze(i lack the scientific skills). the report distinguishes between 3 types of genomic strategies: EST analysis by hgsi,incy and gene.this technique is not adept at providing info on which of the many discovered genes make for good targets for disease intervention.in order to get this info, scientists must perform extensive additional experimentation that correlates a gene's sequence to its function.this process can take months to years to provide relevant info.another drawback of EST analysis is that it has difficulty in identifying genes expressed at low abundance,often the best targets for intervention. positional cloning , practiced by myriad,genset, axys,which is of high quality,but the throughput is too low. glgc's system,READS(restrictive enzyme analysis differentially-expressed sequences) is an automated differential gene system which has the advantage of providing researchers witha birds-eye view of the entire genetic makeup of any tissue.by monitoring the quality of each gene in a way that is highly quantitative,sensitive(can detect genes expressed at 1 copy per cell) and reproducible,overall gene expression profiles of different tissue types can be compared and contrasted. competitor is curagen. comments?thanks. sales